phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion (vol 10, pg 28, 2012)

被引：0
|
作者：
Hamilton, Erika [1 ]
Blackwell, Kimberly [1 ]
Hobeika, Amy C. [2 ]
Clay, Timothy M. [3 ]
Broadwater, Gloria [4 ]
Ren, Xiu-Rong [5 ]
Chen, Wei [5 ]
Castro, Henry [3 ]
Lehmann, Frederic [3 ]
Spector, Neil [1 ]
Wei, Junping [6 ]
Osada, Takuya [6 ]
Lyerly, H. Kim [2 ]
Morse, Michael A. [1 ]
机构：
[1] Duke Univ, Med Ctr, Dept Med, Div Med Oncol, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Dept Surg, Div Gen Surg, Durham, NC 27710 USA
[3] GlaxoSmithKline Biol, Rixensart, Belgium
[4] Duke Canc Inst, Canc Stat Ctr, Durham, NC USA
[5] Duke Univ, Med Ctr, Dept Med, Div Gastroenterol, Durham, NC 27710 USA
[6] Duke Univ, Med Ctr, Dept Surg, Div Surg Sci, Durham, NC 27710 USA
来源：
JOURNAL OF TRANSLATIONAL MEDICINE | 2013年 / 11卷
关键词：
D O I：
10.1186/1479-5876-11-82
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
[No abstract available]
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Translational insights from a phase 1, first-in-human (FIH) clinical trial of the anti-HER2 CAR macrophage CT-0508 in participants with HER2 positive metastatic breast cancer and other HER2 overexpressing solid tumors
    Abdou, Yara
    Mortimer, Joanne
    Pohlmann, Paula
    Johnson, Melissa
    Maziarz, Richard
    Specht, Jennifer M.
    Dees, Claire
    Ueno, Naoto
    Yuan, Yuan
    Angelos, Mathew
    Gill, Saar
    Shestova, Olga
    Serody, Jonathon
    Priceman, Saul
    Qureshi, Rehman
    Sonawane, Poonam
    Pierini, Stefano
    Oliveira-Nunes, Maria Cecilia
    Cushing, Daniel
    Klichinsky, Michael
    Condamine, Thomas
    Swaby, Ramona
    Reiss, Kim
    CANCER RESEARCH, 2024, 84 (09)
  • [32] Phase Ia/Ib trial of the HER2 tyrosine kinase inhibitor zongertinib (BI 1810631) in patients with HER2-driven solid tumors: Focus on Asian patients
    Yoh, K.
    Opdam, F.
    Barve, M.
    Tu, H.
    Wu, Y-L.
    Berz, D.
    Schroeter, L.
    Sadrolhefazi, B.
    Serra, J.
    Heymach, J.
    Yamamoto, N.
    ANNALS OF ONCOLOGY, 2024, 35 : S1637 - S1638
  • [33] Immunotherapy with MVA-BN®-HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells
    Mandl, Stefanie J.
    Rountree, Ryan B.
    Dalpozzo, Katie
    Do, Lisa
    Lombardo, John R.
    Schoonmaker, Peter L.
    Dirmeier, Ulrike
    Steigerwald, Robin
    Giffon, Thierry
    Laus, Reiner
    Delcayre, Alain
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2012, 61 (01) : 19 - 29
  • [34] Immunotherapy with MVA-BN®-HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells
    Stefanie J. Mandl
    Ryan B. Rountree
    Katie Dalpozzo
    Lisa Do
    John R. Lombardo
    Peter L. Schoonmaker
    Ulrike Dirmeier
    Robin Steigerwald
    Thierry Giffon
    Reiner Laus
    Alain Delcayre
    Cancer Immunology, Immunotherapy, 2012, 61 : 19 - 29
  • [35] Beamion Lung 1, an ongoing phase Ia/Ib trial of the HER2 TKI, BI 1810631 in patients (pts) with advanced solid tumors with HER2 aberrations: Latest data
    Opdam, F.
    Heymach, J.
    Ruiter, G.
    Barve, M.
    Tu, H.
    Wu, Y-L.
    Schroeter, L.
    Sadrolhefazi, B.
    Serra, J.
    Yoh, K.
    Yamamoto, N.
    ANNALS OF ONCOLOGY, 2023, 34
  • [36] Updated data from the phase 1 trial of DZD1516, a BBB-penetrant selective HER2 inhibitor, in patients with HER2 positive metastatic breast cancer
    McAndrew, Nicholas P.
    Hu, Xichun
    Zhang, Jian
    Wang, Xiaojia
    Yu, Wenlei
    Pan, Xiaomei
    CANCER RESEARCH, 2023, 83 (05)
  • [37] Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors
    Yap, Timothy A.
    Vidal, Laura
    Adam, Jan
    Stephens, Peter
    Spicer, James
    Shaw, Heather
    Ang, Jooern
    Temple, Graham
    Bell, Susan
    Shahidi, Mehdi
    Uttenreuther-Fischer, Martina
    Stopfer, Peter
    Futreal, Andrew
    Calvert, Hilary
    de Bono, Johann S.
    Plummer, Ruth
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (25) : 3965 - 3972
  • [38] A Phase I Clinical Trial of Autologous HER2 CMV Bispecific CAR T Cells for Progressive Glioblastoma
    Ahmed, Nabil
    Brawley, Vita
    Diouf, Oumar
    Wakefield, Amanda
    Ashoori, Aidin
    Ghazi, Alexia
    Gerken, Claudia
    Yi, Joanna
    Liu, Hao
    Rooney, Cliona M.
    Dotti, Gianpietro
    Gee, Adrian
    Grossman, Robert
    Kew, Yvonne
    Baskin, David
    Zhang, Jonathan
    New, Pamela
    Hicks, John
    Powell, Suzanne Z.
    Wels, Winfried
    Brenner, Malcolm K.
    Heslop, Helen E.
    Gottschalk, Stephen
    MOLECULAR THERAPY, 2015, 23 : S9 - S9
  • [39] Phase II trial of HER2-PET/ CT using 68Ga-anti-HER2 VHH1 for characterization of HER2 presence in brain metastases of breast cancer patients
    Keyaerts, M.
    Xavier, C.
    Everaert, H.
    Vaneycken, I.
    Fontaine, C.
    Decoster, L.
    Vanhoeij, M.
    Caveliers, V.
    Lahoutte, T.
    ANNALS OF ONCOLOGY, 2019, 30
  • [40] A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies
    Filipa Lynce
    Hongkun Wang
    Emanuel F. Petricoin
    Paula R. Pohlmann
    Brandon Smaglo
    Jimmy Hwang
    Aiwu R. He
    Deepa S. Subramaniam
    John Deeken
    John Marshall
    Michael J. Pishvaian
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 1145 - 1151
12345